IQVIA Holdings Inc. (FRA:QTS)
Germany · Delayed Price · Currency is EUR | Market Cap | 31.28B +8.4% |
| Revenue (ttm) | 14.42B +7.3% |
| Net Income | 1.20B +3.8% |
| EPS | 7.00 +9.9% |
| Shares Out | n/a |
| PE Ratio | 26.04 |
| Forward PE | 16.19 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | n/a |
| Open | 191.30 |
| Previous Close | 184.95 |
| Day's Range | 191.30 - 210.60 |
| 52-Week Range | 132.05 - 210.90 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Jul 28, 2026 |
About IQVIA Holdings
IQVIA Holdings Inc. provides clinical research services, commercial insights, and healthcare intelligence to the life sciences and healthcare industries in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions. The Technology & Analytics Solutions segment offers a range of cloud-based applications and associated implementation services; real world solutions that enable life sciences and provider customers ... [Read more]
Financial Performance
In 2025, IQVIA Holdings's revenue was $16.31 billion, an increase of 5.87% compared to the previous year's $15.41 billion. Earnings were $1.36 billion, a decrease of -0.95%.
Financial numbers in USD Financial StatementsNews
This Healthcare Stock Is Today's Best in the S&P 500
IQVIA Holdings leads the index after the company boosted its full-year outlook on the back of a strong second quarter.
IQVIA raises annual profit forecast on clinical research demand
IQVIA Holdings raised its annual profit forecast on Tuesday after reporting better-than-expected second-quarter results, driven by strong demand for its healthcare data and analytics services, sendi...
IQVIA Holdings Earnings Call Transcript: Q2 2026
Second quarter results exceeded guidance, with revenue up 8.7% and adjusted EPS up 12.1% year-over-year. Both clinical and commercial segments showed strong growth, driven by AI-enabled solutions and robust demand. Full-year guidance was raised across all key metrics.
IQVIA Holdings Earnings release: Q2 2026
IQVIA Holdings released its Q2 2026 earnings on July 28, 2026, summarizing the period's financial results.
IQVIA Holdings Slides: Q2 2026
IQVIA Holdings has posted slides in relation to its Q2 2026 quarterly earnings report, which was published on July 28, 2026.
Iqvia reports Q2 EPS $3.15, consensus $3.03
Reports Q2 revenue $4.368B, consensus $4.3B. “In a strengthening market environment, the IQVIA (IQV) team executed well and delivered outstanding results, exceeding the high-end of our expectations fo...
IQVIA Reports Second-Quarter 2026 Results
RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--IQVIA Holdings Inc. (“IQVIA”) (NYSE:IQV), a leading global provider of clinical research services, commercial insights and healthcare intelligence to the...
IQVIA's Dr. Cynthia Verst Testifies Before Congressional Subcommittee on More Efficient Path to Early Clinical Development in the United States
RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--IQVIA (NYSE:IQV), a leading global provider of clinical research services, commercial insights and healthcare intelligence to the life sciences and healt...
Iqvia price target raised to $230 from $215 at Mizuho
Mizuho analyst Ann Hynes raised the firm’s price target on Iqvia (IQV) to $230 from $215 and keeps an Outperform rating on the shares. The firm adjusted targets in the…
Iqvia named short-term buy idea at Deutsche Bank
Deutsche Bank placed a “Catalyst call: Buy” on shares of Iqvia (IQV) as a short-term investment idea. Iqvia has traded down 10% year-to-date and has underperformed peers despite 2026 guidance…
IQVIA to Announce Second-Quarter 2026 Results on July 28, 2026
RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--IQVIA Holdings Inc. (“IQVIA”) (NYSE:IQV), a leading global provider of clinical research services, commercial insights and healthcare intelligence to the...
Iqvia price target raised to $240 from $210 at HSBC
HSBC analyst Sidharth Sahoo raised the firm’s price target on Iqvia (IQV) to $240 from $210 and keeps a Buy rating on the shares. In a sector note on Healthcare,…
Iqvia price target raised to $249 from $230 at Baird
Baird raised the firm’s price target on Iqvia (IQV) to $249 from $230 and keeps an Outperform rating on the shares. The firm designated the shares as a bullish Freah…
StackAdapt Teams Up with IQVIA Digital's MediaOS to Power Healthcare Advertising
TORONTO--(BUSINESS WIRE)--StackAdapt (www.stackadapt.com), the leading AI advertising and orchestration platform, today announced a collaboration with IQVIA Digital to advance more relevant and compli...
Iqvia downgraded to Equal Weight from Overweight at Morgan Stanley
Morgan Stanley analyst Kallum Titchmarsh downgraded Iqvia (IQV) to Equal Weight from Overweight with a price target of $200, down from $225. The firm struggles to identify “clear drivers of…
Wiley and IQVIA Release Cross-Sector Report on AI's Promise and Pressure Points Across Healthcare Value Chain
HOBOKEN, N.J.--(BUSINESS WIRE)--Wiley (NYSE: WLY) and IQVIA (NYSE: IQV) today released Scientific Discovery & AI: The Science-to-Patient Journey, a cross-sector intelligence report drawing on candid d...
IQVIA Announces Pricing of Senior Notes
RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--IQVIA Holdings Inc. (“IQVIA”) (NYSE:IQV) today announced that its wholly owned subsidiary, IQVIA Inc. (the “Issuer”), priced an offering of €950,000,000 ...
IQVIA Holdings Transcript: Jefferies Global Healthcare Conference 2026
The conference highlighted strong Q1 performance, with both clinical and commercial segments exceeding expectations. AI is accelerating operational efficiency and revenue, while demand is rebounding across large pharma and EBP, supported by increased outsourcing and specialized engagement.
Iqvia price target lowered to $210 from $240 at HSBC
HSBC lowered the firm’s price target on Iqvia (IQV) to $210 from $240 and keeps a Buy rating on the shares. The firm says market expectations on life science tools…
IQVIA Announces Offering of Senior Notes
RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--IQVIA Holdings Inc. (“IQVIA”) (NYSE:IQV) today announced that its wholly owned subsidiary, IQVIA Inc. (the “Issuer”), intends to raise €950,000,000 throu...
IQVIA CEO to Speak at Jefferies Global Healthcare Conference
RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--IQVIA Holdings Inc. (“IQVIA”) (NYSE:IQV), a leading global provider of clinical research services, commercial insights and healthcare intelligence to the...
Iqvia, Kexing expand strategic collaboration
Iqvia (IQV) is advancing its strategic collaboration with Kexing Biopharm to support a global, multi-product biosimilar development and commercialization program. The collaboration is designed to supp...
IQVIA and Kexing Biopharm Expand Strategic Collaboration to Accelerate Global Biosimilar Development using AI-Enabled Capabilities
RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--IQVIA (NYSE:IQV), a leading global provider of clinical research services, commercial insights and healthcare intelligence to the life sciences and healt...
IQVIA Holdings Transcript: Bank of America Global Healthcare Conference 2026
Q1 results exceeded expectations with strong growth in both commercial and RDS segments, supported by robust demand and AI-driven productivity. AI adoption is accelerating across top pharma clients, driving new offerings and operational efficiencies. Capital deployment favors buybacks, with ongoing M&A activity and increased investment in AI initiatives.